BioLargo (NASDAQ:BLGO – Get Free Report) is one of 32 public companies in the “Chemicals & allied products” industry, but how does it contrast to its competitors? We will compare BioLargo to related businesses based on the strength of its dividends, analyst recommendations, valuation, institutional ownership, earnings, risk and profitability.
Earnings and Valuation
This table compares BioLargo and its competitors revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
BioLargo | $12.23 million | -$3.50 million | -8.16 |
BioLargo Competitors | $6.84 billion | $211.64 million | 69.50 |
BioLargo’s competitors have higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Analyst Recommendations
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
BioLargo | 0 | 0 | 0 | 0 | N/A |
BioLargo Competitors | 139 | 1251 | 1567 | 44 | 2.51 |
As a group, “Chemicals & allied products” companies have a potential upside of 13.55%. Given BioLargo’s competitors higher probable upside, analysts plainly believe BioLargo has less favorable growth aspects than its competitors.
Profitability
This table compares BioLargo and its competitors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
BioLargo | -16.53% | -58.35% | -32.12% |
BioLargo Competitors | -591.84% | 5.15% | -0.65% |
Risk & Volatility
BioLargo has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500. Comparatively, BioLargo’s competitors have a beta of 1.81, indicating that their average stock price is 81% more volatile than the S&P 500.
Institutional and Insider Ownership
0.0% of BioLargo shares are held by institutional investors. Comparatively, 70.6% of shares of all “Chemicals & allied products” companies are held by institutional investors. 20.3% of BioLargo shares are held by insiders. Comparatively, 10.6% of shares of all “Chemicals & allied products” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
BioLargo competitors beat BioLargo on 8 of the 10 factors compared.
About BioLargo
BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.
Receive News & Ratings for BioLargo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLargo and related companies with MarketBeat.com's FREE daily email newsletter.